{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:23:49Z","timestamp":1782512629680,"version":"3.54.5"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:00:00Z","timestamp":1369094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nrcardio.2013.73","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T10:23:15Z","timestamp":1369131795000},"page":"397-409","source":"Crossref","is-referenced-by-count":18,"title":["Oral anticoagulants in the management of venous thromboembolism"],"prefix":"10.1038","volume":"10","author":[{"given":"John N.","family":"Makaryus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe F.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,21]]},"reference":[{"key":"BFnrcardio201373_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","volume":"113","author":"J Steffel","year":"2006","unstructured":"Steffel, J., Luscher, T. F. & Tanner, F. C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113, 722\u2013731 (2006).","journal-title":"Circulation"},{"key":"BFnrcardio201373_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857\u2013867 (2007).","journal-title":"Ann. Intern. Med."},{"issue":"Suppl. 2","key":"BFnrcardio201373_CR3","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1378\/chest.1412S3","volume":"141","author":"GH Guyatt","year":"2012","unstructured":"Guyatt, G. H. et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (Suppl. 2), 7S\u201347S (2012).","journal-title":"Chest"},{"key":"BFnrcardio201373_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5482\/ha-12050008","volume":"32","author":"J Steffel","year":"2012","unstructured":"Steffel, J. & Luscher, T. F. Vitamin K antagonists: ready to be replaced? Hamostaseologie 32, 249\u2013257 (2012).","journal-title":"Hamostaseologie"},{"key":"BFnrcardio201373_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/14656566.2011.528754","volume":"12","author":"MA Giorgi","year":"2011","unstructured":"Giorgi, M. A., Cohen Arazi, H., Gonzalez, C. D. & Di Girolamo, G. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opin. Pharmacother. 12, 567\u2013577 (2011).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrcardio201373_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.thromres.2008.05.010","volume":"123","author":"S Harder","year":"2008","unstructured":"Harder, S., Parisius, J. & Picard-Willems, B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb. Res. 123, 396\u2013403 (2008).","journal-title":"Thromb. Res."},{"key":"BFnrcardio201373_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.blre.2011.04.003","volume":"25","author":"B Brenner","year":"2011","unstructured":"Brenner, B. & Hoffman, R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Rev. 25, 215\u2013221 (2011).","journal-title":"Blood Rev."},{"key":"BFnrcardio201373_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech, S., Ebner, T., Ludwig\u2013Schwellinger, E., Stangier, J. & Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386\u2013399 (2008).","journal-title":"Drug Metab. Dispos."},{"key":"BFnrcardio201373_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier, J., Rathgen, K., Stahle, H. & Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49, 259\u2013268 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrcardio201373_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","volume":"64","author":"J Stangier","year":"2007","unstructured":"Stangier, J., Rathgen, K., Stahle, H., Gansser, D. & Roth, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 64, 292\u2013303 (2007).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrcardio201373_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J van Ryn","year":"2010","unstructured":"van Ryn, J. et al. Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116\u20131127 (2010).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR12","doi-asserted-by":"crossref","unstructured":"Schulman, S. et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [abstract 205]. Presented at the American Society of Hematology 2011 Annual Meeting.","DOI":"10.1182\/blood.V118.21.205.205"},{"key":"BFnrcardio201373_CR13","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson, B. I. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 5, 2178\u20132185 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201373_CR14","doi-asserted-by":"crossref","unstructured":"RE-MOBILIZE Writing Committee et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24, 1\u20139 (2009).","DOI":"10.1016\/j.arth.2008.01.132"},{"key":"BFnrcardio201373_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson, B. I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949\u2013956 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio201373_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1160\/TH10-10-0679","volume":"105","author":"BI Eriksson","year":"2011","unstructured":"Eriksson, B. I. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial. Thromb. Haemost. 105, 721\u2013729 (2011).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR17","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman, S. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342\u20132352 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1517\/14656561003674397","volume":"11","author":"P Prandoni","year":"2010","unstructured":"Prandoni, P. & Taher, A. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). Expert Opin. Pharmacother. 11, 1035\u20131037 (2010).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrcardio201373_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman, S. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 368, 709\u2013718 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans, A. L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127, 634\u2013640 (2013).","journal-title":"Circulation"},{"key":"BFnrcardio201373_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","volume":"172","author":"K Uchino","year":"2012","unstructured":"Uchino, K. & Hernandez, A. V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. 172, 397\u2013402 (2012).","journal-title":"Arch. Intern. Med."},{"key":"BFnrcardio201373_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","volume":"30","author":"E Perzborn","year":"2010","unstructured":"Perzborn, E. et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol. 30, 376\u2013381 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio201373_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/TA.0b013e318265cf9e","volume":"73","author":"LM Baumann Kreuziger","year":"2012","unstructured":"Baumann Kreuziger, L. M., Morton, C. T. & Dries, D. J. New anticoagulants: a concise review. J. Trauma Acute Care Surg. 73, 983\u2013992 (2012).","journal-title":"J. Trauma Acute Care Surg."},{"key":"BFnrcardio201373_CR24","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"388","author":"BI Eriksson","year":"2008","unstructured":"Eriksson, B. I. et al. Rivaraoxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 388, 2765\u20132775 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar, A. K. et al. Extended duration rivaroxaban versus short term enoxaparin for the prevention of VTE after total hip arthroplasty. Lancet 372, 31\u201339 (2008).","journal-title":"Lancet"},{"key":"BFnrcardio201373_CR26","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen, M. R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776\u20132786 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR27","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie, A. G. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet 373, 1673\u20131680 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio201373_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.thromres.2011.01.016","volume":"127","author":"S Turun","year":"2011","unstructured":"Turun, S. et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb. Res. 127, 525\u2013534 (2011).","journal-title":"Thromb. Res."},{"key":"BFnrcardio201373_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1111096","volume":"368","author":"AT Cohen","year":"2013","unstructured":"Cohen, A. T. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N. Engl. J. Med. 368, 513\u2013523 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan, N. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37, 74\u201381 (2009).","journal-title":"Drug Metab. Dispos."},{"key":"BFnrcardio201373_CR31","doi-asserted-by":"crossref","unstructured":"EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499\u20132510 (2010).","DOI":"10.1056\/NEJMoa1007903"},{"key":"BFnrcardio201373_CR32","doi-asserted-by":"crossref","unstructured":"EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287\u20131297 (2012).","DOI":"10.1056\/NEJMoa1113572"},{"key":"BFnrcardio201373_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ejh.12002","volume":"89","author":"P Prandoni","year":"2012","unstructured":"Prandoni, P. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur. J. Haematol. 89, 281\u2013287 (2012).","journal-title":"Eur. J. Haematol."},{"key":"BFnrcardio201373_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1586\/erc.11.62","volume":"9","author":"E Romualdi","year":"2011","unstructured":"Romualdi, E., Donadini, M. P. & Ageno, W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev. Cardiovasc. Ther. 9, 841\u2013844 (2011).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFnrcardio201373_CR35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen, M. R. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594\u2013604 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen, M. R. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375, 807\u2013815 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio201373_CR37","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen, M. R. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363, 2487\u20132498 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR38","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","volume":"365","author":"SZ Goldhaber","year":"2011","unstructured":"Goldhaber, S. Z. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365, 2167\u20132177 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR39","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrcardio201373_CR40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli, G. et al. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 368, 699\u2013708 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"CT Ruff","year":"2010","unstructured":"Ruff, C. T. et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160, 635\u2013641 (2010).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201373_CR42","doi-asserted-by":"publisher","unstructured":"Raskob, G. et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J. Thromb. Haemost. http:\/\/dx.doi.org\/10.1111\/jth.12230 .","DOI":"10.1111\/jth.12230"},{"key":"BFnrcardio201373_CR43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","volume":"111","author":"CH Yeh","year":"2012","unstructured":"Yeh, C. H., Fredenburgh, J. C. & Weitz, J. I. Oral direct factor Xa inhibitors. Circ. Res. 111, 1069\u20131078 (2012).","journal-title":"Circ. Res."},{"key":"BFnrcardio201373_CR44","doi-asserted-by":"crossref","unstructured":"Fuji, T., Fujita, S., Tachibana, S. & Kawai, Y. Edoxaban versus enoxaparin for the prevention of venous thromboembolism and bleeding from STARS E-3 and STARS J.-V [abstract 208]. Presented at the American Society of Hematology 2011 Annual Meeting.","DOI":"10.1182\/blood.V118.21.208.208"},{"key":"BFnrcardio201373_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5482\/HAMO-12-05-0004","volume":"32","author":"I Ahrens","year":"2012","unstructured":"Ahrens, I. & Bode, C. Oral anticoagulation with edoxaban. Focus on current phase III clinical development. Hamostaseologie 32, 212\u2013215 (2012).","journal-title":"Hamostaseologie"},{"key":"BFnrcardio201373_CR46","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1160\/TH10-02-0142","volume":"104","author":"G Raskob","year":"2010","unstructured":"Raskob, G. et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study. Thromb. Haemost. 104, 642\u2013649 (2010).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR47","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/j.1538-7836.2010.04021.x","volume":"8","author":"T Fuji","year":"2010","unstructured":"Fuji, T. et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J. Thromb. Haemost. 8, 2458\u20132468 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201373_CR48","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1160\/TH11-07-0469","volume":"106","author":"G Piazza","year":"2011","unstructured":"Piazza, G. et al. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb. Haemost. 106, 1095\u20131102 (2011).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR49","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.amjmed.2011.12.004","volume":"125","author":"G Piazza","year":"2011","unstructured":"Piazza, G. et al. Venous thromboembolism in patients with diabetes mellitus. Am. J. Med. 125, 709\u2013716 (2011).","journal-title":"Am. J. Med."},{"key":"BFnrcardio201373_CR50","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMoa022157","volume":"348","author":"P Prandoni","year":"2003","unstructured":"Prandoni, P. et al. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 348, 1435\u20131441 (2003).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrcardio201373_CR51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1538-7836.2007.02467.x","volume":"5","author":"P Prandoni","year":"2007","unstructured":"Prandoni, P. Venous thromboembolism and atherosclerosis: is there a link? J. Thromb. Haemost. 5 (Suppl. 1), 270\u2013275 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201373_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1365-2796.2007.01815.x","volume":"262","author":"P Prandoni","year":"2007","unstructured":"Prandoni, P. Links between arterial and venous disease. J. Intern. Med. 262, 341\u2013350 (2007).","journal-title":"J. Intern. Med."},{"key":"BFnrcardio201373_CR53","first-page":"e362","volume":"127","author":"PT O'Gara","year":"2013","unstructured":"O'Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation 127, e362\u2013e425 (2013).","journal-title":"Circulation"},{"key":"BFnrcardio201373_CR54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.293.6.681","volume":"293","author":"JN Fiessinger","year":"2005","unstructured":"Fiessinger, J. N. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293, 681\u2013689 (2005).","journal-title":"JAMA"},{"key":"BFnrcardio201373_CR55","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14934-3","volume":"362","author":"SB Olsson","year":"2003","unstructured":"Olsson, S. B. et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691\u20131968 (2003).","journal-title":"Lancet"},{"key":"BFnrcardio201373_CR56","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jama.293.6.690","volume":"293","author":"GW Albers","year":"2005","unstructured":"Albers, G. W. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293, 690\u2013698 (2005).","journal-title":"JAMA"},{"key":"BFnrcardio201373_CR57","doi-asserted-by":"publisher","first-page":"E571","DOI":"10.1016\/S0735-1097(12)60572-5","volume":"59","author":"R Artang","year":"2012","unstructured":"Artang, R., Rome, E. & Vidaillet, H. Dabigatran and myocardial infarction, drug or class effect: meta-analysis of randomized trials with oral direct thrombin inhibitors [abstract]. J. Am. Coll. Cardiol. 59, E571 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201373_CR58","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archinternmed.2012.4026","volume":"172","author":"A Komocsi","year":"2012","unstructured":"Komocsi, A., Vorobcsuk, A., Kehl, D. & Aradi, D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch. Intern. Med. 172, 1537\u20131545 (2012).","journal-title":"Arch. Intern. Med."},{"key":"BFnrcardio201373_CR59","unstructured":"Thomas, K. A promising drug with a flaw. The New York Times (2 November 2012)."},{"key":"BFnrcardio201373_CR60","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg, E. S. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573\u20131579 (2011).","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"BFnrcardio201373_CR61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1538-7836.2009.03429.x","volume":"7","author":"MA Crowther","year":"2009","unstructured":"Crowther, M. A. & Warkentin, T. E. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J. Thromb. Haemost. 7 (Suppl. 1), 107\u2013110 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201373_CR62","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1160\/TH12-03-0179","volume":"108","author":"R Marlu","year":"2012","unstructured":"Marlu, R. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 108, 217\u2013224 (2012).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR63","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J van Ryn","year":"2010","unstructured":"van Ryn, J. et al. Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116\u20131127 (2010).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR64","doi-asserted-by":"publisher","unstructured":"Akwaa, F. & Spyropoulos, A. C. Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. Curr. Treat. Options Cardiovasc. Med. http:\/\/dx.doi.org\/10.1007\/s11936-013-0238-5 .","DOI":"10.1007\/s11936-013-0238-5"},{"key":"BFnrcardio201373_CR65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","volume":"116","author":"A Godier","year":"2012","unstructured":"Godier, A. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116, 94\u2013102 (2012).","journal-title":"Anesthesiology"},{"key":"BFnrcardio201373_CR66","doi-asserted-by":"crossref","unstructured":"Hollenbach, S. J. et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model [abstract 3414]. Presented at the American Society of Hematology 2012 Annual Meeting.","DOI":"10.1182\/blood.V120.21.3414.3414"},{"issue":"Suppl. 1","key":"BFnrcardio201373_CR67","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1002\/ajh.23202","volume":"87","author":"S Kaatz","year":"2012","unstructured":"Kaatz, S. et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am. J. Hematol. 87 (Suppl. 1), S141\u2013S145 (2012).","journal-title":"Am. J. Hematol."},{"key":"BFnrcardio201373_CR68","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1160\/TH09-03-0176","volume":"103","author":"MM Samama","year":"2010","unstructured":"Samama, M. M. et al. Assessment of laboratory assays to measure rivaroxaban\u2014an oral, direct factor Xa inhibitor. Thromb. Haemost. 103, 815\u2013825 (2010).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR69","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","volume":"72","author":"BK Poulsen","year":"2012","unstructured":"Poulsen, B. K., Grove, E. L. & Husted, S. E. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 72, 1739\u20131753 (2012).","journal-title":"Drugs"},{"key":"BFnrcardio201373_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11886-010-0085-x","volume":"12","author":"U Baber","year":"2010","unstructured":"Baber, U., van der Zee, S. & Fuster, V. Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation. Curr. Cardiol. Rep. 12, 133\u2013139 (2010).","journal-title":"Curr. Cardiol. Rep."},{"key":"BFnrcardio201373_CR71","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jacc.2012.06.039","volume":"60","author":"J Price","year":"2012","unstructured":"Price, J., Hynes, M., Labinaz, M., Ruel, M. & Boodhwani, M. Mechanical valve thrombosis with dabigatran. J. Am. Coll. Cardiol. 60, 1710\u20131711 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201373_CR72","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","volume":"163","author":"F Van de Werf","year":"2012","unstructured":"Van de Werf, F. et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am. Heart J. 163, 931\u2013937, e1 (2012).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201373_CR73","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","volume":"143","author":"JA Heit","year":"2005","unstructured":"Heit, J. A. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann. Intern. Med. 143, 697\u2013706 (2005).","journal-title":"Ann. Intern. Med."},{"key":"BFnrcardio201373_CR74","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","volume":"194","author":"AH James","year":"2006","unstructured":"James, A. H., Jamison, M. G., Brancazio, L. R. & Myers, E. R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol. 194, 1311\u20131315 (2006).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"BFnrcardio201373_CR75","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0049-3848(84)90260-3","volume":"34","author":"F Forestier","year":"1984","unstructured":"Forestier, F., Daffos, F. & Capella-Pavlovsky, M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb. Res. 34, 557\u2013560 (1984).","journal-title":"Thromb. Res."},{"key":"BFnrcardio201373_CR76","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1055\/s-0038-1646558","volume":"61","author":"JS Ginsberg","year":"1989","unstructured":"Ginsberg, J. S., Hirsh, J., Turner, D. C., Levine, M. N. & Burrows, R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb. Haemost. 61, 197\u2013203 (1989).","journal-title":"Thromb. Haemost."},{"key":"BFnrcardio201373_CR77","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jth.12085","volume":"11","author":"E Romualdi","year":"2013","unstructured":"Romualdi, E. et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J. Thromb. Haemost. 11, 270\u2013281 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201373_CR78","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.beha.2012.07.006","volume":"25","author":"AF Jacobsen","year":"2012","unstructured":"Jacobsen, A. F. & Sandset, P. M. Venous thromboembolism associated with pregnancy and hormonal therapy. Best Pract. Res. Clin. Haematol. 25, 319\u2013332 (2012).","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"Suppl. 10","key":"BFnrcardio201373_CR79","doi-asserted-by":"publisher","first-page":"S294","DOI":"10.1097\/01.CCM.0000183157.15533.4C","volume":"33","author":"SE Stone","year":"2005","unstructured":"Stone, S. E. & Morris, T. A. Pulmonary embolism during and after pregnancy. Crit. Care Med. 33 (Suppl. 10), S294\u2013S300 (2005).","journal-title":"Crit. Care Med."},{"key":"BFnrcardio201373_CR80","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT Sorensen","year":"2000","unstructured":"Sorensen, H. T., Mellemkjaer, L., Olsen, J. H. & Baron, J. A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846\u20131850 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201373_CR81","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew, H. K., Wun, T., Harvey, D., Zhou, H. & White, R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458\u2013464 (2006).","journal-title":"Arch. Intern. Med."},{"key":"BFnrcardio201373_CR82","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","volume":"27","author":"NM Kuderer","year":"2009","unstructured":"Kuderer, N. M., Ortel, T. L. & Francis, C. W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J. Clin. Oncol. 27, 4902\u201311 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrcardio201373_CR83","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","volume":"9","author":"F Horsted","year":"2012","unstructured":"Horsted, F., West, J. & Grainge, M. J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 9, e1001275 (2012).","journal-title":"PLoS Med."},{"key":"BFnrcardio201373_CR84","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrclinonc.2012.106","volume":"9","author":"A Young","year":"2012","unstructured":"Young, A. et al. Thrombosis and cancer. Nat. Rev. Clin. Oncol. 9, 437\u2013449 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrcardio201373_CR85","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman, G. H. et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490\u20135505 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrcardio201373_CR86","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee, A. Y. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146\u2013153 (2003).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrcardio201373_CR87","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/S0049-3848(12)70027-0","volume":"129","author":"M Verso","year":"2012","unstructured":"Verso, M. & Agnelli, G. New and old anticoagulants in cancer. Thromb. Res. 129 (Suppl. 1), S101\u2013S105 (2012).","journal-title":"Thromb. Res."},{"key":"BFnrcardio201373_CR88","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jth.12070","volume":"11","author":"D Farge","year":"2013","unstructured":"Farge, D. et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 11, 56\u201370 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201373_CR89","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2009.24.7346","volume":"27","author":"MN Levine","year":"2009","unstructured":"Levine, M. N. New antithrombotic drugs: potential for use in oncology. J. Clin. Oncol. 27, 4912\u20134918 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrcardio201373_CR90","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1160\/TH08-07-0460","volume":"101","author":"AG Turpie","year":"2009","unstructured":"Turpie, A. G. et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb. Haemost. 101, 68\u201376 (2009).","journal-title":"Thromb. Haemost."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.73.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.73","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.73.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:53:24Z","timestamp":1684468404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,21]]},"references-count":90,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnrcardio201373"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2013.73","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,21]]}}}